Synedgen is a bio-pharmaceutical company that uses a comprehensive approach to develop polysaccharide derivatives that minimize or treat infections by targeting sites where bacteria enter the human body and encourage healing after infection or acute and chronic damage. The company was formed in 2009 through the merger of BioSTAR West and Hawaii Chitopure, and is managed by an experienced team of scientists and business executives. Synedgen's drugs target the complex interactions at the cell surface and mucosal interface to suppress inflammation, reduce infection, and improve healing at surfaces, providing physicians with improved quality of life for their patients with diseases of the GI tract and pulmonary tree.